Fenwick represented Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, in its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of $31.00 per share, which includes 675,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $160.4 million.
J.P. Morgan, Piper Sandler and Stifel acted as the joint bookrunning managers for the offering. RBC Capital Markets and Needham & Company acted as the lead managers for the offering. More information can be obtained from the company’s announcement.
The Fenwick transaction team was led by corporate partners Michael Brown and Amanda Rose and included associates Jennifer Hitchcock, Annie Omata, Alyssa Zhang and Duey Ho.